Table 1 Baseline characteristics of the RNOP-09 cohort as compared to the patients enrolled into the EORTC 26981/NCIC-CE.3 trial.
Baseline characteristics | ||
|---|---|---|
Treatment | ||
RNOP-09 (N = 63) | EORTC/NCI-C/NCI-C (N = 287) | |
N (%) | N (%) | |
Sex | ||
Female | 23 (36.5) | 102 (35.5) |
Male | 40 (63.5) | 185 (64.5) |
Age (class) | ||
<= 50 | 19 (30.2) | 95 (33.1) |
51-60 | 19 (30.2) | 109 (38.0) |
>60 | 25 (39.7) | 83 (28.9) |
Performance status (KPS) | ||
90-100% | 22 (34.9) | 113 (39.4) |
80% | 33 (52.4) | 136 (47.4) |
70% | 8 (12.7) | 38 (13.2) |
Extent of surgery | ||
Complete | 28 (44.4) | 113 (39.4) |
Partial | 23 (36.5) | 126 (43.9) |
Biopsy | 9 (14.3) | 48 (16.7) |
Not recorded | 3 (4.8) | 0 (0.0) |
Corticosteroids at study entry | ||
No | 39 (61.9) | 94 (32.8) |
Yes | 18 (28.6) | 193 (67.2) |
Missing data | 6 (9.5) | 0 (0.0) |
MGMT promoter | ||
Methylated | 16 (25.4) | 46 (16.0) |
Unmethylated | 17 (27.0) | 60 (20.9) |
Missing | 30 (47.6) | 181 (63.1) |
Survival at evaluation | ||
Alive | 22 (34.9) | 33 (11.5) |
Dead | 41 (65.1) | 254 (88.5) |
Progression free survival at evaluation | ||
Not progressive and alive | 7 (11.1) | 15 (5.2) |
Progressive or dead | 56 (88.9) | 272 (94.8) |